Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...

HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, a biotechnology company pioneering dual-payload antibody-drug conjugates (ADCs) as targeted cancer therapies, today announced the closing of a $10 million ...

Novartis has agreed to acquire Myricx Bio, a privately held UK-based biotechnology company developing a new class of antibody ...

CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload antibody-drug conjugates (ADCs) today announced a definitive agreement to be ...

Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact ...

Deal terms include $1.1B upfront and up to $400M milestones, positioning Novartis to internalize an N‑myristoyltransferase inhibitor payload platform for next-generation ADC development. Myricx’s lead ...

LAUSANNE, Switzerland & DAEJEON, Republic of Korea--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company dedicated to developing innovative ...

Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), entered into a licensing agreement with Qurient, a ...

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

IDEAYA has exercised the option for an exclusive worldwide license on Biocytogen’s potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (BsADC), BCG034 (IDE034) This ...

The e-posters will be available for browsing at the AACR virtual meeting platform beginning at 12:00 PM PT on April 17, as well as on the OBI Pharma website (www.obipharma.com) beginning on April 18.